peter attia glp-1 320 – AMA 64: New insights on agonists (Ozempic, Wegovy, Mounjaro) - efficacy, benefits, risks, and considerations in the rapidly evolving weight-loss drug landscape - The Drive New insights on GLP-1 agonists—Ozempic,

KPV and tributyrin partner to regulate damaging cytokines associated with inflammatory bowel disease, while BPC-157 and PEA calm and fortify the GI lining [8, 30, 31, 32]

The primary pathophysiology of Parkinsons disease is the death of dopaminergic neurons (dopamine-producing cells) and motoneurons in the midbrain (substantia nigra region)

10.1056/NEJMe1814706 N

Bonaventura J, Rico AJ, Moreno E, Sierra S, Snchez M, Luquin N, et al

has served on scientific advisory panels and/or speaker's bureaus and served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Fractyl, Gubra, Merck Sharp & Dohme, Novo Nordisk, Sanofi and Zealand Pharma